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Nicotine Strongly Activates Dendritic Cell–Mediated
Adaptive Immunity
Potential Role for Progression of Atherosclerotic Lesions
Alexandra Aicher, MD*; Christopher Heeschen, MD*; Mariette Mohaupt, PhD;
John P. Cooke, MD, PhD; Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Antigen-presenting cells (APCs) such as monocytes and dendritic cells (DCs) stimulate T-cell proliferation
and activation in the course of adaptive immunity. This cellular interaction plays a role in the growth of atherosclerotic
plaques. Nicotine has been shown to increase the growth of atherosclerotic lesions. Therefore, we investigated whether
nicotine can stimulate APCs and their T cell–stimulatory capacity using human monocyte–derived DCs and murine
bone marrow–derived DCs as APCs.
Methods and Results—Nicotine dose-dependently (108 to 104 mol/L) induced DC expression of costimulatory molecules
(ie, CD86, CD40), MHC class II, and adhesion molecules (ie, LFA-1, CD54). Moreover, nicotine induced a 7.0-fold
increase in secretion of the proinflammatory TH1 cytokine interleukin-12 by human DCs. These effects were abrogated
by the nicotinic receptor antagonist -bungarotoxin and mecamylamine, respectively. The effects of nicotine were
mediated in part by the phosphorylation of the PI3 kinase downstream target Akt and the mitogen-activated kinases ERK
and p38 MAPK. Nicotine-stimulated APCs had a greater capacity to stimulate T-cell proliferation and cytokine
secretion, as documented by mixed lymphocyte reactions and ovalbumin-specific assays with ovalbumin-transgenic
DO10.11 mice. In a murine model of atherosclerosis, nicotine significantly enhanced the recruitment of DCs to
atherosclerotic lesions in vivo.
Conclusions—Nicotine activates DCs and augments their capacity to stimulate T-cell proliferation and cytokine secretion.
These effects of nicotine may contribute to its influence on the progression of atherosclerotic lesions. (Circulation.
2003;107:604-611.)
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Nicotine is a major component of cigarette smoke, awidely accepted risk factor for atherosclerosis. It is
not known how and to what extent nicotine contributes to
the adverse effects of chronic tobacco use, apart from its
psychoactive actions and addictive properties. Nicotine
activates nicotinic acetylcholine (nACh) receptors that
belong to a family of ionotropic receptors and consist of 5
transmembrane subunits building up ion channels. The
nACh receptors are widely distributed throughout the
central and peripheral nervous system and are involved in
signal transmission at the skeletal neuromuscular junction,
in autonomic ganglia, and in the brain. In addition,
nonneuronal cells such as monocytes, endothelial cells,
and epithelial cells also express nACh receptors.1– 4 How-
ever, the effect of nicotine on immune cells is incompletely
characterized and controversial. Some investigators have
provided evidence that nicotine promotes inflammation.5,6
By contrast, other studies indicate that nicotine may have
immunosuppressive effects, although these results were
achieved with relatively high doses of nicotine.7 Moreover,
nicotine was recently demonstrated to promote progression
of advanced atherosclerotic plaques.8 This may result in
ischemia and infarction of the heart. Innate and adaptive
immune responses play a crucial role for the growth and
instability of atherosclerotic plaques.9 Recently, dendritic
cells (DCs) were detected in the arterial wall.10,11 DCs are
potent antigen-presenting cells required for the initiation
of adaptive immune responses.12 The number of DCs is
increased in atherosclerotic lesions, suggesting that DCs
might contribute to T-cell activation in atherosclerosis.13
Proinflammatory factors can induce maturation of DCs
corresponding to a switch from a phagocytic stage to a
stage of strong T cell–stimulatory capacity. Accordingly,
we examined the effect of nicotine in activation of DCs
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and on their ability to activate T-cell proliferation and
cytokine secretion.
Methods
Reagents
Nicotine [1-methyl-2-(3-pyridyl)pyrrolidine] was obtained from
Sigma and tested for potential endotoxin contamination by use of the
Endotox assay (Sigma). In addition, to further exclude a contribution
of endotoxin to our results, we performed some experiments in the
presence of 5 g/mL polymyxin B (Sigma) that binds and neutralizes
lipid A, the active moiety of lipopolysaccharide (LPS). LPS from
Salmonella minnesota Re595 as well as the nicotinic receptor
antagonists -bungarotoxin and mecamylamine were purchased
from Sigma. The p38 mitogen-activated protein kinase (MAPK)
inhibitor SB203580 was obtained from Alexis, the MEK inhibitor
PD98059 from Biomol, and the phosphatidylinositol-3-kinase
(PI3K) inhibitor LY294002 from Calbiochem. Human granulocyte-
macrophage colony stimulating factor (GM-CSF; Leucomax) was
from Novartis, and interleukin-4 (IL-4) was bought from R&D.
Murine GM-CSF was obtained from supernatants of NIH-3T3 cells
transfected with murine GM-CSF (provided by Thomas Blanken-
stein). FITC-dextran (40 000 kDa) and carboxyfluorescein diacetate
succinimidyl ester (CFSE) were purchased from Molecular Probes.
Synthetic ovalbumin (OVA) peptide representing amino acids 323 to
339 of chicken OVA was obtained from Biosynthan.
Animals
OVA-specific DO11.10 transgenic mice (BALB/c background, I-Ad)
to obtain OVA-specific T lymphocytes were purchased from Charles
River (Sulzbach, Germany). Murine bone marrow–derived DCs as
stimulator cells were prepared from sex-matched BALB/c mice
(Charles River). Annexin V, 7-aminoactinomycin D (AAD), and
CD3-FITC were purchased from BD Pharmingen. CD40L (CD154)
was from Beckman Coulter.
Preparation of Human Monocytes and
Monocyte-Derived Human DCs
Human monocytes and DCs were prepared as previously described14
and were stimulated with nicotine for 12 hours.
Bone Marrow–Derived Murine DCs
Bone marrow–derived DCs were prepared as previously decribed.15
Mixed Lymphocyte Reactions
For the mixed lymphocyte reactions (MLRs), allogeneic CD3 T
lymphocytes were isolated from peripheral blood by immunomag-
netic beads (Milteny Biotech). To measure their proliferation, CD3
T cells were labeled with the fluorescent dye CFSE. With each cell
division, the fluorescence intensity of the cells is reduced by half.16
After thorough washing to remove unbound fluorescent dye, 200 000
CD3 T cells were mixed with human DCs and monocytes as
stimulators (to ratios of 1:10 and 1:50, DCs/monocytes:T cells).
Antigen-presenting cells were prestimulated with nicotine (107
mol/L) for 12 hours before use in MLRs. Experiments were
performed in 96-well plates in triplicate. After 3 days of coculture of
DCs or monocytes together with T cells in 200 L RPMI containing
5% FCS, supernatants were collected, stored at70°C, and analyzed
by ELISA for production of human IL-2, a marker of T-cell
activation. Cell pellets were washed with PBS and stained with
mouse anti-human CD4-allophycocyanin (BD Pharmingen). Finally,
costaining of CD4-allophycocyanin with CFSE labeling was deter-
mined by FACS analysis.
OVA-Specific Proliferation Assay
Lymph nodes from OVA-specific DO11.10 transgenic BALB/c
(H-2d) mice were homogenized to obtain single-cell suspensions.
Lymphocytes from total lymph nodes contained more than 50%
CD4 T cells and were labeled with CFSE dye. Bone marrow–
derived DCs from BALB/c mice were prestimulated with nicotine
Figure 1. 7-nACh receptor is expressed by human DCs and
upregulated by nicotine. Human DCs (106 DCs/mL) were starved
in RPMI 1640 medium  0.5% FCS for at least 6 hours and
then exposed to nicotine (108 or 107 mol/L) for 12 hours
before FACS analysis. A representative FACS analysis out of 3
is shown.
Figure 2. Nicotine induces expression of CD86 on human DCs
(A). FACS analysis revealed that nicotine induced a dose-
dependent increase in mean fluorescence intensity of costimula-
tory molecule CD86 by human DCs. Effect of nicotine was
blocked by nicotinic receptor antagonist mecamylamine. Data
are given as meanSEM (n3; P0.01). Nicotine-dependent
cytotoxicity (B). In presence of graded doses of nicotine, per-
centage of dead cells as annexin V/7-AAD cells was deter-
mined by FACS analysis. Data are given as meanSEM (n4;
P0.01).
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(107 mol/L) for 12 hours. To assess their T cell–stimulatory
capacity, 104 DCs were first loaded with 0.1 and 1 g/mL OVA for
2 hours, washed twice with PBS, and then mixed with 105 CD4
DO11.10 transgenic T cells. After 3 days of coculture, supernatants
were examined for murine IL-2 secretion. Cell pellets were washed,
stained with CD4-allopyocyanine, and prepared for FACS analysis
of CFSE fluorescence.
Flow Cytometric Measurement
Human DCs were blocked with 5% human hyperimmune globulin
(Flebogamma, Grifols) for human cells and rat anti-mouse CD32
F(ab)2 antibody (BD Pharmingen) at 5 g/mL in PBS for murine
cells at room temperature for 10 minutes. Then, cells were incubated
with mouse anti-human CD11a-FITC, CD18-FITC, CD54-FITC,
CD83-FITC, CD86-FITC, HLA-DR-FITC (all from BD Pharmin-
gen), and CD40-FITC (Serotec). Surface expression of the nicotinic
receptor was detected with mouse anti-human nicotinic receptor
(Sigma) followed by goat anti-mouse F(ab)2 antibody (Dako). To
characterize murine DCs, rat anti-mouse CD40-FITC, CD54-FITC,
CD86-FITC, and I-Ad-FITC (MHC class II) were used (all from BD
Pharmingen). Finally, cells were fixed in 1% formaldehyde/PBS and
analyzed by FACSCalibur (Becton Dickinson) using CellQuest
software (BD Pharmingen). Cell fluorescence intensity obtained with
a specific antibody was in each case compared with that obtained
with isotype-matched control antibodies purchased from BD Pharm-
ingen. All FACS data were analyzed on 10 000 cells per condition.
Endocytosis Assays
To assess endocytosis of the DC preparations, FITC-dextran was
used according to a method described previously.17 Briefly, cells
stimulated with nicotine or unstimulated were incubated in complete
RPMI medium with FITC-dextran at a final concentration of 1
mg/mL at 37°C for 30 minutes. Background staining at 4°C was used
as reference. After the cells had been washed, FITC-dextran uptake
of immature DCs was determined by FACS.
Quantification of Cytokine Production
Human IL-12p40 and human and murine IL-2 were measured by
ELISA (OptEIA Set, BD Pharmingen). Human IL-10 was measured
with a high-sensitivity ELISA (R&D). To detect cytokines, super-
natants of 106 APCs/mL were used.
Western Blot Analyses
For analysis of ERK 1/2, p38 MAPK, and Akt phosphorylation,
proteins were obtained in lysis buffer as previously described.18
Protein lysates (30 g/mL) were electrophoresed on 10% SDS-
PAGE gels, transferred to PVDF membranes (Millipore), and blotted
with polyclonal phospho-ERK antibodies (New England BioLabs),
followed by anti-rabbit horseradish peroxidase (Santa Cruz Biotech-
nology) and detection by chemiluminescence ECL (Amersham).
Antibodies to phospho-p38 MAPK or phospho-Akt (Santa Cruz)
were used to analyze phospho-p38 MAPK and phospho-Akt expres-
sion. As loading controls, antibodies against tubulin (Labvision
Corp) were used.
DC Recruitment Assay
Apolipoprotein (apo)E–knockout mice were purchased from Jack-
son Laboratories as retired breeders (males with C57BL/6J back-
ground). Fifty-week-old animals fed a normal chow diet were used
for experiments. Bone marrow–derived murine DCs from wild-type
C57BL/6J were labeled with CSFE (1 mol/L) for 10 minutes at
37°C. After 3 washing steps, 106 DCs were resuspended in 200 L
RPMI containing 0.5% FCS and injected intravenously via the tail
vein. Starting 3 days before the injection of the DCs, animals were
treated with vehicle or nicotine (1 g per 10 g body weight twice
daily) via subcutaneous injection. Forty-eight hours after the injec-
tion of the DCs, mice were killed and perfused with 4% formalde-
hyde with 20 mol/L EDTA by injection through the apex of the left
ventricle. The base of the heart and the ascending aorta were isolated
and mounted in TissueTek (Sakura) freezing medium. We analyzed
the atheroma of the aortic root using native cryostat sections (10
m). Serial sections spanning 1.0 mm of the ascending aorta at the
level of the sinus of Valsalva were examined under light and
fluorescence microscopy. The number of CSFE-labeled DCs at-
tached to the intimal surface or in atheromatous plaques was
quantified for each aorta.19,20
Statistical Analysis
All results for continuous variables are expressed as medianSEM
intervals. Comparisons between groups were analyzed by t test
(2-sided) or ANOVA for experiments with more than 2 subgroups.
Post hoc range tests and pairwise multiple comparisons were
performed with the t test (2-sided) with Bonferroni adjustment.
Comparison of categorical variables was generated by the Pearson 2
Figure 3. Nicotine enhances expression
of surface molecules involved in inflam-
mation. A, Costimulatory (CD86), adhe-
sion (CD54), and MHC class II molecules
(HLA-DR) are strongly upregulated in
human DCs after stimulation with nico-
tine as revealed by FACS analysis. B,
Histographic presentation of FACS anal-
yses on expression of surface molecules
involved in inflammation. C, Similar
effects of nicotine are observed in DCs
from BALB/c mice, with upregulation of
CD54, CD86, CD40, and MHC class II
molecules (I-Ad). This figure is represen-
tative of 3 similar experiments performed
on different donors or mice.
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test. All analyses were performed with SPSS 11.0 (SPSS Inc).
Probability values of P0.05 were considered statistically
significant.
Results
Expression of the Nicotinic Receptor on Human
Monocyte–Derived DCs
To explore the role of nicotine and its receptors in DCs, we
first tested whether nicotinic receptors are expressed on
monocyte-derived DCs and their precursors, the monocytes.
One of the most abundant nicotinic receptors is the 7-
nicotinic receptor, whose constitutive expression was demon-
strated on both DCs (Figure 1) and monocytes (data not
shown). Moreover, stimulation with its ligand nicotine up-
regulated the expression of the 7-nicotinic receptor in a
dose-dependent manner.
Nicotine-Induced Upregulation of
Proinflammatory Surface Molecules and Cytokines
in Human and Murine DCs
CD86 is an essential costimulatory molecule on DCs required
for efficient T-cell stimulation. Without sufficient costimula-
tion, stimulation of T cells will induce anergy and apoptosis
of T cells. Using increasing doses of nicotine (108 to 106
mol/L), we observed an increase in CD86 expression that
peaked at 107 mol/L (Figure 2A; also shown in Figure 3A).
Higher concentrations (104 mol/L) resulted in decreased
expression of CD86 compared with control cells. This reflects
the increasing toxicity of nicotine concentrations higher than
105 mol/L, as shown in Figure 2B. In contrast, lower doses
of nicotine tended to reduce the number of dead cells
(P0.07). To confirm that upregulation of CD86 is a result of
stimulation of nACh receptors (using the optimal nicotine
dose of 107 mol/L), we preincubated DCs with the broad-
spectrum nicotinic antagonist mecamylamine (107 mol/L).
Mecamylamine abrogated the nicotine-induced upregulation
of CD86 (Figure 2A).
Moreover, nicotine (107 mol/L) increased the DC expres-
sion of adhesion molecules such as the 2-integrin LFA-1
(CD11a/CD18) and its ligand CD54 (ICAM-1) in human DCs
(Figure 3, A and B). In addition, nicotine also increased the
expression of the MHC class II molecule HLA-DR and
induced the expression of the DC maturation marker CD83 in
human DCs (Figure 3B). Nicotine had similar effects on
murine DCs. In murine DCs, nicotine increased the expres-
sion of CD54, the MHC class II molecule I-Ad, and the
costimulatory molecule CD40 (Figure 3C).
Nicotine induced a marked increase in the secretion of the
proinflammatory cytokine IL-12 p40 by DCs as detected by
ELISA (Figure 4A). These effects of nicotine were blocked
by mecamylamine and the selective 7-nACh receptor antag-
onist -bungarotoxin. The proinflammatory effect of nicotine
caused a compensatory upregulation of the antiinflammatory
cytokine IL-10 (Figure 4B).
Nicotine Augments the Ability of DCs to
Stimulate T Cells
We next determined whether nicotine could enhance the
ability of DCs to stimulate T cells by use of allogeneic MLRs
(Figure 5A). Nicotine-stimulated DCs markedly increased the
T-cell secretion of IL-2, consistent with T-cell activation. The
effect of nicotine (107 mol/L) was similar to that of the
potent activator LPS (100 ng/mL). Nicotine-stimulated
monocytes also induced IL-2 production in allogeneic T
lymphocytes but less efficiently than DCs (Figure 5B). To
determine whether nicotine stimulation is also effective in
promoting antigen-specific responses, we studied its effects
on the ability of OVA-exposed murine DCs to stimulate
proliferation in DO11.10 OVA-transgenic T cells (Figure
5C). Nicotine significantly enhanced the T cell–stimulatory
capacity of syngeneic murine DCs presenting OVA peptide
Figure 4. Nicotine-induced IL-12 p40 (A) and IL-10 (B) production in
human DCs is delivered through nACh receptors. DCs were preincu-
bated 30 minutes before nicotine stimulation (107 mol/L) with specific
7-nACh receptor antagonist -bungarotoxin and broad-spectrum
nACh receptor antagonist mecamylamine. Both inhibitors were used
at 107 mol/L. IL-12 p40 secretion in response to nicotine stimulation
could be strongly inhibited in presence of -bungarotoxin and
mecamylamine. Data are meanSEM (n3).
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323 to 339 to OVA-transgenic T lymphocytes. Compared
with vehicle-treated cells, nicotine-treated human DCs in-
creased the proliferation of allogeneic CD4 T cells by more
than 3-fold; a similar effect was observed in nicotine-treated
monocytes (2.2-fold induction) (Figure 5D). Similarly, nico-
tine stimulation led to a 2.3-fold increase in proliferation of
syngeneic OVA-specific DO11.10 transgenic T cells. Simi-
larly, nicotine stimulation led to a 2.3-fold increase in
proliferation of syngeneic OVA-specific DO11.10 trans-
genic T cells. In addition, nicotine-stimulated DCs signif-
icantly increased expression of CD40L (CD154) on T cells
in DC–T-cell cocultures (Figure 5E). Acquisition of T-
cell–stimulatory capacity in maturing DCs is inversely
correlated to their capacity for endocytosis of antigens
such as FITC-dextran. Consistent with its effect to activate
DCs, nicotine reduced their capacity for endocytosis
(Figure 5F).
Nicotine Stimulation Activates MAPK and Akt
Pathways in Human DCs
To gain insight into nicotine-induced signaling, we deter-
mined whether MAPKs and Akt might be involved in
nicotine-induced signaling pathways in human DCs. Nicotine
rapidly increased the phosphorylation of p38 MAPK, an
effect that was visible within 5 minutes (Figure 6A). Maximal
activation of p38 MAPK was achieved by 15 minutes
(54786% increase), declining after 30 minutes. Phosphor-
ylation of the MAPK ERK reached a maximal induction
(33234% increase) after 30 minutes of nicotine stimulation
(Figure 6B). Activation of the Akt pathway, however, peaked
relatively late, at 60 minutes, with a 41878% increase
(Figure 6C).
Role for MAPK and Akt in the Nicotine-Induced
Upregulation of the Costimulatory Molecule CD86
in Human DCs
Having defined signaling pathways that are activated in
nicotine-stimulated human DCs, we examined the role of
Figure 5. Functional improvement of
antigen-presenting cells after stimulation
with nicotine (107 mol/L). In MLRs of
human DCs mixed with allogeneic T lym-
phocytes, nicotine-prestimulated DCs
(black bars) induced T-cell activation,
which was measured as secretion of T
cell–specific cytokine IL-2. Similar activa-
tion was obtained by standard doses
(100 ng/mL) of LPS (stippled bars) (A).
Similar T cell–stimulatory effects of nico-
tine could be found for monocytes (MCs)
along with allogeneic T cells but to a
lesser extent than DCs (B). To also prove
stimulating effects of nicotine for antigen-
specific assays, we used OVA-peptide–
loaded murine DCs in combination with
OVA-transgenic T cells (C). To assess
T-cell proliferation in response to alloge-
neic nicotine-prestimulated human DCs
or monocytes, we measured loss of
incorporated CSFE labeling by FACS
analysis, resulting in cells with lower lev-
els of fluorescence of CSFE. To detect T
helper cells, we performed a dual stain-
ing together with allopyocyanine-labeled
CD4 antibodies (D). Nicotine-stimulated
DCs significantly enhanced CD40L
(CD154) expression on T cells in DC–T-
cell cocultures as assessed by CD3-
FITC/CD40L-PE double stainings (E).
Enhanced T-cell–stimulatory capacity of
nicotine-stimulated human DCs is paral-
leled by a decrease in internalization of
soluble antigens such as FITC-dextran
(F). Data are given as meanSEM (n3)
and representative FACS analyses out of
3 independent experiments are chosen.
Figure 6. Nicotine (107 mol/L) activates MAPK and Akt path-
ways in human DCs. Phosphorylation of p38 MAPK (A), ERK (B),
and Akt (C) is shown in representative Western blots (n5).
Tubulin is used as loading control.
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these signaling pathways in nicotine-induced expression of
the costimulatory molecule CD86. The MAP kinase (MEK)
inhibitor PD98059 and the inhibitor of p38 MAPK SB203580
each abolished the nicotine-induced increase in CD86 expres-
sion (Figure 7). Likewise, nicotine-induced CD86 upregula-
tion was completely dependent on activation of PI3K/Akt
pathways, because it was abrogated by the PI3K inhibitor
LY294002 (Figure 7).
DC Homing to Atherosclerotic Lesions
To investigate whether nicotine affects DCs in vivo, DCs
were labeled with CSFE and injected into apoE-deficient
mice. Atherosclerotic plaques above the aortic valve at the
level of the sinus of Valsalva are the most advanced lesions
in apoE-deficient mice. Sections of the aortic root were
analyzed with fluorescent microscopy for CSFE-labeled DCs
that were adherent to or within the atherosclerotic plaques.
The majority of the labeled DCs were detected in regions
inside the plaque, suggesting transmigration of the labeled
DCs across the endothelial cell layer (Figure 8, A and B).
Forty-eight hours after intravenous injection, DC homing to
atherosclerotic lesions was significantly enhanced by nico-
tine. Adjusting for differences in plaque area, we found
significantly more DCs in the nicotine group (34.210.9
DCs/lesion) than the control group (11.05.1; P0.001). In
contrast, atherosclerotic lesions in apoE-deficient mice with-
out DC injection showed only background fluorescence (data
not shown).
Discussion
The present study suggests an important role for nicotine in
DC activation. This was evidenced by the upregulation of
nACh receptors, costimulatory molecules such as CD86 and
CD40, MHC class molecules such as HLA-DR, and adhesion
molecules such as CD54. Moreover, nicotine enhances the
ability of DCs and monocytes to stimulate T-cell proliferation
and cytokine production in allogeneic MLRs and antigen-
specific assays. This indicates that nicotine enhances adaptive
immunity and pathophysiological processes that involve
adaptive immunity, such as atherosclerosis. Indeed, we dem-
onstrate that nicotine significantly enhanced DC homing to
atherosclerotic lesions.
DCs act as sentinels, which are highly specialized in
sampling antigens from sites of inflammation.12,21 In athero-
sclerosis, possible antigens relevant for the initiation and
progression of atherosclerotic lesions might be oxidized LDL,
2-glycoprotein I, and heat-shock proteins.22 These antigens
are actually self-antigens, modified by oxidation in the case
of LDL. Prolonged presentation of self-antigens by DCs is
crucial for the development of destructive autoimmune re-
sponses.23 In autoimmune disease, antigen-specific activation
of autoimmune T cells is based on the interactions of T-cell
receptors with self-antigens presented by MHC molecules on
DCs. The capacity of DCs to stimulate T cells depends on
their stage of maturation: after DCs picked up antigens at
their immature phagocytic stage, DCs move to the regional
lymph nodes while undergoing maturation.12 Maturation
boosts their capacity to efficiently present antigens to T cells
and is mediated by upregulation of costimulatory molecules
such as CD86 (B7.2) and CD40. Costimulation by the ligands
CD80/86 and its receptor CD28 on T cells is required for
efficient T-cell stimulation.24 Lack of costimulation leads to
T-cell anergy and apoptosis. Moreover, MHC class II mole-
cules are upregulated and the possibility of DC–T-cell en-
counters is favored by enhanced expression of adhesion
Figure 7. Inhibitors of MAPK and PI3K abrogate effect of nicotine
on CD86 expression. A, Human DCs were pretreated with vehicle
or p38 MAPK inhibitor SB203580 (10 mol/L), MEK inhibitor
PD98059 (50 mol/L), and PI3K inhibitor LY294002 (10 mol/L) 30
minutes before stimulation with nicotine (107 mol/L). Representa-
tive FACS analyses out of 3 are shown, and data are presented as
meanSEM. B, Histographic presentation of FACS data.
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molecules. In parallel, activated DCs secrete cytokines and
chemokines to recruit more immune cells to the site of
inflammation. Thus, T cells present in atherosclerotic lesions
may be nonspecifically activated T cells or those that have
been expanded within lymph nodes in recognition of the
presented antigen.
Nicotine at physiologically relevant concentrations pro-
motes progression of advanced atherosclerotic lesions, an
effect that was inhibited in part by the specific COX-2
inhibitor rofecoxib.8 Rofecoxib has powerful antiinflamma-
tory properties that, together with its antiangiogenic effect,
may have contributed to the inhibition of lesion progression.
In our experiments, nicotine had a maximal immunostimula-
tory effect at concentrations between 108 and 107 mol/L,
which can be found in the plasma of smokers.25 Because
atherogenesis is known to rely on both innate and adaptive
immune responses, it is tempting to speculate that nicotine-
enhanced activation of DCs might contribute to T-cell recruit-
ment and acceleration of inflammation in the atherosclerotic
lesions. Indeed, soluble factors such as IL-12 released by
activated DCs are well established to contribute to the
formation of atherosclerotic lesions and plaque destabiliza-
tion.26 In addition, nicotine stimulated DC expression of
CD40. Ligation of CD40 can induce IL-12 production in
DCs.14 Moreover, genetic disruption of the CD40/CD40
ligand system has been described to prevent the initiation and
progression of atherosclerosis.27
Antagonists of the 7-nicotinic receptors blocked the ef-
fects of nicotine on DC maturation. The nACh receptors are
ligand-gated ionotropic channels consisting of -subunits or a
combination of - and -subunits, each of which has a unique
pharmacological profile.28 Intriguingly, we observed a
marked expression of the homopentamer 7-nACh receptor in
DCs. The 7-nACh receptor appears to play a crucial role in
the observed effects of nicotine on DC maturation. The
specific 7-nACh receptor antagonist -bungarotoxin abro-
gated the stimulatory effects of nicotine, an effect similar to
what we observed for the nonselective nACh receptor antag-
onist mecamylamine.
The downstream effector pathways by which nicotine
activated DCs appear to rely on the activation of several
kinases. Here, we demonstrated activation of ERK1/2, p38
MAPK, and Akt in DCs by nicotine. Activation of ERK 1/2
and Akt is consistent with the effect of nicotine in other cell
types, which is mediated via the 7-nACh receptor.29–31
However, p38 MAPK has not yet been involved in activation
by nicotine.32 Notably, the p38 MAPK pathway is involved in
the LPS-induced upregulation of costimulatory molecules via
stimulation of transcription factors such as nuclear
factor-B.33
Finally, nicotine profoundly enhanced homing of DCs to
atherosclerotic lesions in vivo, which supports the hypothesis
that the proatherogenic effect of nicotine may be mediated in
part by recruiting DCs to sites of chronic inflammation such
as atherosclerotic plaques. DCs clustering with T cells have
been identified in atherosclerotic lesions of apoE-deficient
mice and form clusters with T cells.34
Because tobacco smoke consists of more than 4000 chem-
ical constituents, it is impossible to predict the effect of
nicotine within this complex mixture of components. Al-
though we show that nicotine has a potent immunostimula-
tory effect, there are several molecules in cigarette smoke that
may be toxic to DCs (eg, cadmium, reactive oxygen species;
see Powell35 for review). The net effect of cigarette smoke on
endothelial function may be quite different from that of
nicotine alone. In addition, our results are in contrast to
several studies showing a decrease in immune responses in
the presence of nicotine.7 However, these studies used much
higher doses of nicotine that, in our experiments, showed
cytotoxic effects, which cannot be reversed by nACh receptor
antagonists (Figure 2).
In conclusion, the present study indicates that nicotine
enhances adaptive immunity, an effect that is mediated by
nicotinic ACh receptors on DCs and monocytes. Nicotine
activates these antigen-presenting cells, inducing the expres-
sion of surface molecules involved in inflammation and
augmenting T-cell proliferation and cytokine secretion. These
effects of nicotine together with the enhanced recruitment of
DCs to atherosclerotic lesions may contribute to pathophys-
iological processes involved in the growth and destabilization
of atherosclerotic plaques.
Figure 8. Murine model of atherosclero-
sis: cross sections of aortic root of mice
treated with vehicle (A) or nicotine (B).
Homing of CSFE-labeled DCs was signif-
icantly enhanced by nicotine treatment
(subcutaneous injection of 1 g nicotine
per 10 g body weight twice daily). Repre-
sentative pictures are shown (n3).
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